Intellipharmaceutics Announces Second Quarter 2021 Results
ACCESSWIRE
16 Jul 2021, 06:55 GMT+10
TORONTO, ON / ACCESSWIRE / July 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ('Intellipharmaceutics' or the 'Company'), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources on non-exclusive bases. However, there can be no assurance that the products previously licensed to Tris Pharma will be successfully commercialized and produce significant revenues for us.